EHMT2 and breast carcinoma: Furthermore, the inhibition of G9a drastically impairs the proliferation of breast cancer cell lines from various subtypes, including luminal A, claudin-low TNBC, and basal-like TNBC, underscoring its potential as a therapeutic target across these subtypes.